# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-345820
Filing Date
2026-08-12
Accepted
2026-08-12 08:15:13
Documents
79
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | ck0001540171-20260630.htm iXBRL | 10-Q | 3265753
2 | EX-31.1 | ck0001540171-ex31_1.htm | EX-31.1 | 17562
3 | EX-31.2 | ck0001540171-ex31_2.htm | EX-31.2 | 17301
4 | EX-32.1 | ck0001540171-ex32_1.htm | EX-32.1 | 9832
5 | EX-32.2 | ck0001540171-ex32_2.htm | EX-32.2 | 9854
| Complete submission text file | 0001193125-26-345820.txt |  | 11059039

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | ck0001540171-20260630.xsd | EX-101.SCH | 1156897
82 | EXTRACTED XBRL INSTANCE DOCUMENT | ck0001540171-20260630_htm.xml | XML | 1975266

Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Filer) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-43251 | Film No.: 261265409
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)